Pot Compound Reduces Anxiety In First Ever Clinical Trial

Sao Paulo, Brazil: The administration of the cannabinoid cannabidiol (CBD), a non-psychoactive component of marijuana, reduces anxiety in subjects with social anxiety disorder (SAD), according to clinical trial data published online in The Journal of Psychopharmacology.

Investigators at the University of Sao Paulo in Brazil assessed the anti-anxiety activity of oral doses of CBD in ten subjects in a double blind, placebo-controlled trial.

Researchers concluded, “CBD reduces anxiety in SAD and that this is related to its effects on activity in limbic and paralimbic brain areas.”

The study is the first clinical trial to investigate the effects of CBD on human pathological anxiety and its underlying brain mechanisms.

Previous studies of CBD have demonstrated the compound to possess anti-inflammatory activity, anti-cancer activity, and neuroprotective effects – among other therapeutic properties.

For more information, please contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report,” appears online in The Journal of Psychopharmacology.